DNLI Denali Therapeutics
- 18.560
- +0.100+0.54%
- 18.650
- +0.090+0.48%
Denali Therapeutics News
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SATO VICKI L
Denali Therapeutics | 10-Q: Quarterly report
Denali Therapeutics | 8-K: Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics | DEF 14A: Definitive information statements
Denali Therapeutics | DEFA14A: Others
Denali Therapeutics | ARS: Annual Report to Security Holders
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SATO VICKI L
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Krognes Steve E.
Denali Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watts Ryan J.
Denali Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SATO VICKI L
Denali Therapeutics | D: Filing D
Denali Therapeutics | 10-K: Annual report
Denali Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Denali Therapeutics | 8-K: Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Denali Therapeutics | 8-K: Current report
Denali Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SATO VICKI L
Analysis
Price Target
No Data
